Global Bioidentical Hormones Market Segmentation, By Type (Estrogens, Progesterone, Testosterone, Combined Hormones, Others), Product Type (Tablets and Capsules, Creams and Gels, Injectable, Patches and Implants, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospital, Gynaecology Clinics, Academic and Research, Others) – Industry Trends and Forecast to 2031.
Bioidentical Hormones Market Analysis
In today’s fast pacing and stressful, experiencing hormonal imbalance is normal especially in women. With various kinds of hormonal changes, the female body develops diseases and abnormalities which is worsened by ageing. Hormonal imbalance invites problems such as weight gain, memory decline, fatigue, and muscle loss.
Bioidentical Hormones Market Size
Global bioidentical hormones market size was valued at USD 3.81 billion in 2023 and is projected to reach USD 6.35 billion by 2031, with a CAGR of 6.61% during the forecast period of 2024 to 2031.
Report Scope and Market Segmentation
|
Attributes
|
Bioidentical Hormones Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Key Market Players
|
SottoPelle (US), Novartis AG (Switzerland), Orion Pharma AB (Sweden), Full Life Wellness Center (US), BioTE Medical, LLC (US), Merck KGaA (Germany), Pfizer Inc. (US), TherapeuticsMD, Inc. (US), Papillon Medical (Canda), United Pharmacy (US), Noven Pharmaceuticals, Inc. (US), GEA Group Aktiengesellschaft (Germany), Novo Nordisk A/S (Denmark), GeneScience Pharmaceuticals Co., Ltd. (China), Actiza Pharmaceutical Private Limited (India), Defy Medical (US), Neuva Aesthetics (US), ZRT Laboratory (US), Bayer AG (Germany) and Allergan (Ireland)
|
Bioidentical Hormones Market Definition
Bioidentical hormones are manmade hormones which are used to treat low or out of balance hormonal levels. Bioidentical hormones are similar to the hormones that are naturally produced in the body of both men and women. Bioidentical hormones are used to treat the hormonal imbalance and its effects on and in the body. Normally, hormonal imbalance in men is experienced after 40 years of age.
Bioidentical Hormones Market Dynamics
Drivers
- The rise in the prevalence of hormonal deficiency
Surging prevalence of hormonal deficiency especially in women all around the globe owing to various internal and external factors is one of the major factors responsible for fostering growth of the market. Rising patient pool especially in the developing economies is carving the way for the growth of the market.
- Research and development proficiencies
Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies have led to the advancements in the medical technology and have improved the quality of healthcare facilities. Increasing number of screening tests for research proficiencies has further widened the scope of growth.
- Government investments on healthcare infrastructure
The increase in the funding by the federal government is set to drive the growth of the market. Moreover, growth and expansion of healthcare industry being driven by both public and private players especially in the developing economies will create lucrative personal health devices market growth opportunities. Also, growing acceptance of bioidentical hormones replacement therapy by the governmental healthcare facilities is also bolstering the market growth rate.
Additionally, surge in the personal disposable income level, introduction of technologically driven product in hospitals and increasing investment for the development of advanced and rise in focus on women health care and treatment of hormonal imbalances, positively affect the market growth rate.
Opportunities
Furthermore, upsurge in the public-private funding for target research activities, increasing need for improvised healthcare services owing to imbalance between health workforce and patients and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2022 to 2029. Additionally, surging number of strategic collaborations, rising lifestyle changes, increased stress and work pressure, irregular eating habits, and lack of exercise, growing number of hospitals and laboratories, rising geriatric population base, rising number of cross-industry partnerships and collaborations and increasing per capita expenditure on health care will further expand the market's growth rate in the future.
Restraints/Challenges
On the other hand, high cost associated with the research and development proficiencies, safety issues related to the use of compound bioidentical hormones and difficulties related with the medical procedures are expected to obstruct market growth. Also, lack of favourable reimbursement scenario and technology penetration in the developing economies, various side effects such as weight loss and blurred vision, high risk of heart attack and breast cancer and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2024-2031.
This bioidentical hormones market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bioidentical hormones market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on Bioidentical Hormones Market
Covid-19 has had a negative impact on the market. Reduced focus on non-essential medical procedures and postponement of healthcare procedures has put a dent on the market growth rate. Moreover, halt on the number of research and development proficiencies further restricted the scope of growth in the pandemic phase.
Bioidentical Hormones Market Scope
The bioidentical hormones market is segmented on the basis of type, product type, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Estrogens
- Progesterone
- Testosterone
- Combined Hormones
- Others
On the basis of type, the bioidentical hormones market is segmented into estrogens, progesterone, testosterone, combined hormones and others.
Product type
- Tablets and Capsules
- Creams and Gels
- Injectable
- Patches and Implants
- Others
Based on product type, the bioidentical hormones market is segmented into tablets and capsules, creams and gels, injectable, patches and implants and others.
Distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
On the basis of distribution channel, the bioidentical hormones market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
End user
- Hospital
- Gynaecology Clinics
- Academic and Research
- Others
The end user segment of the bioidentical hormones market is segmented into hospital, gynaecology clinics, academic and research and others.
Bioidentical Hormones Market Regional Analysis
The bioidentical hormones market is analysed and market size insights and trends are provided by country, type, product type, distribution channel and end user as referenced above.
The countries covered in the bioidentical hormones market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the bioidentical hormones market because of the strong base of healthcare facilities, availability of reimbursements, rising geriatric population, high healthcare spending combined with the onset of COVID-19 pandemic and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, ever-rising geriatric population base and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The bioidentical hormones market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for bioidentical hormones market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bioidentical hormones market. The data is available for historic period 2010-2020.
Bioidentical Hormones Market Share
The bioidentical hormones market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bioidentical hormones market.
Bioidentical Hormones Market Leaders Operating in the Market Are:
- SottoPelle (US)
- Novartis AG (Switzerland)
- Orion Pharma AB (Sweden)
- Full Life Wellness Center (US)
- BioTE Medical, LLC (US)
- Merck KGaA (Germany)
- Pfizer Inc. (US)
- TherapeuticsMD, Inc. (US)
- Papillon Medical (Canda)
- United Pharmacy (US)
- Noven Pharmaceuticals, Inc. (US)
- GEA Group Aktiengesellschaft (Germany)
- Novo Nordisk A/S (Denmark)
- GeneScience Pharmaceuticals Co., Ltd. (China)
- Actiza Pharmaceutical Private Limited (India)
- Defy Medical (US)
- Neuva Aesthetics (US)
- ZRT Laboratory (US)
- Bayer AG (Germany)
- Allergan (Ireland)
Latest Developments in Bioidentical Hormones Market
- In August 2020, the US FDA approved Sogroya (somapacitan), a human growth hormone (HGH) therapy for adult patients with growth hormone deficiency, which is indicated to be taken once a week by injection under the skin.
- In December 2020, the US FDA approved Thyquidity (levothyroxine) oral solution, of VistaPharm, for replacement therapy of primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital.
- In December 2020, the US FDA approved the Myovant Sciences' Orgovyx (relugolix), which is an orally administered treatment.
- In August 2020, Bayer AG announced the acquisition of KanDy Therapeutics Inc., which aids in the expansion of Bayer's women's drug pipeline by adding KanDy's menopause drug to its portfolio.
SKU-